IR Overview

James Noble, our CEO, on our Full Year 2018 Financial Results and Business Update


Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patient’s own T-cells to express our SPEAR TCRs to target and potentially destroy tumors.


Our wholly-owned pipeline includes SPEAR T-cell therapies targeting ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4), and ADP-A2AFP (AFP), which are being investigated in clinical studies across multiple solid tumor indications. We continue to build a pipeline of further proprietary TCR therapeutic candidates, second generation treatment options, as well as allogeneic (off-the-shelf) solutions.


We believe our approach will lead to SPEAR T-cells with the potential to significantly impact cancer treatment and the clinical outcomes of cancer patients.

$4.21 Stock is Down 0.19 (4.32%)
ADAP (American Depositary Shares)
ExchangeNASDAQ GS (US Dollar)
Volume36,696
Today's Open$4.40
Previous Close$4.40
Data as of 04/24/19 9:56 a.m.
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent NewsMore >>
DateTitle 
04/18/19Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
- Presentation to include overview of substantial progress of Adaptimmune’s off-the-shelf SPEAR T-cell platform - - Data will show that hiPSC-derived allogeneic SPEAR T-cells have a T-cell phenotype and demonstrate tumor antigen-specific activation in vitro - PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 18, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces an oral presentation by Dr. Jo Brewer, VP of Platform S... 
Printer Friendly Version
04/02/19Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
PHILADELPHIA and OXFORD, United Kingdom, April 02, 2019 (GLOBE NEWSWIRE) --  Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety data from two patients with advanced hepatocellular carcinoma (HCC), liver cancer, from the first dose cohort of the ADP-A2AFP study at the annual AACR meeting. “We did not observe clinically significant liver toxicity in the two patients treated at a dose of 100 million transduced cells, and these data ... 
Printer Friendly Version
04/01/19Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
- Preclinical data show that next generation SPEAR T-cells may improve long term T-cell functions as well as antitumor activity - PHILADELPHIA and OXFORD, United Kingdom, April 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented promising preclinical data at the annual AACR meeting from its next generation SPEAR T-cell targeting MAGE-A4. This next generation SPEAR T-cell, known as ADP-A2M4CD8, expresses the CD8α co-rec... 
Printer Friendly Version
02/27/19CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
PHILADELPHIA and OXFORD, United Kingdom, Feb. 27, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Adaptimmune Therapeutics plc (Nasdaq:ADAP), please note that the third subheadline should read, "Treating patients in expansion phases of all ADP-A2M10 and ADP-A2M4 studies at target doses of 5 billion cells (with doses up to 10 billion cells)," specifically "5 billion cells" rather than "1 billion cells" as previously stated. Additionally, under the "Building... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
05/02/19 11:30 a.m.
through
05/02/19 11:45 p.m. ET
Differentiating T-Cells from hiPSCs to Create Off-The-Shelf SPEAR T-Cell Therapies
05/08/19
Adaptimmune at Sun Trust Life Sciences Summit in NYC for 1:1 meetings
LocationLotte New York Palace
455 Madison Avenue at 50th Street
New York, NY 10022
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.